HIV/AIDS Topics People with Well-Controlled HIV Can Match Lifespan of HIV Negatives
- Details
- Category: HIV Treatment
- Published on Wednesday, 19 June 2013 00:00
- Written by Liz Highleyman
People with HIV who are able to achieve good viral suppression and CD4 cell recovery on antiretroviral therapy (ART) have a mortality rate similar to that of uninfected people in the general population, according to results from the large SMART and ESPRIT studies, published in the March 27, 2013 issue of AIDS.
New NRTI BMS-986001 Potently Suppresses HIV in Early Monotherapy Study
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 19 June 2013 00:00
- Written by Liz Highleyman
BMS-986001, a novel thymidine nucleoside reverse transcriptase inhibitor (NRTI) being developed by Bristol-Myers Squibb, demonstrated good antiviral activity and appeared safe and well-tolerated in a 10-day monotherapy study, researchers reported in the July 1, 2013, Journal of Acquired Immune Deficiency Syndromes.
30 Years of HIV: Long Road Ahead to a Cure
- Details
- Category: Search for a Cure
- Published on Thursday, 13 June 2013 00:00
- Written by Keith Alcorn
Scientists from around the world met to review the future of HIV scientific research at the Institut Pasteur in Paris, last month -- 30 years after the discovery of HIV by a team based at the institute. The prospects for a cure for HIV infection were a major theme of the meeting, which attracted around 500 scientists, chiefly from France and the United States.
Younger People with HIV Are Missing Out in the Continuum of Care
- Details
- Category: HIV Treatment
- Published on Wednesday, 19 June 2013 00:00
- Written by Liz Highleyman
Young people with HIV are less likely to access and benefit from HIV care and treatment at all levels of the "care cascade" from testing to starting antiretroviral therapy (ART) to achieving viral suppression, according to findings reported in the June 17, 2013, advance edition of JAMA Internal Medicine. Overall, only about 25% of HIV positive people achieved undetectable viral load.
GRACE Survey Sheds Light on Treatment Benefits and Barriers for HIV+ Women
- Details
- Category: Approved HIV Drugs
- Published on Thursday, 06 June 2013 00:00
- Written by Janssen
Caring for children, unemployment, and transportation difficulties were among the factors most likely to lead to poor adherence, early dropout, and suboptimal response to antiretroviral therapy (ART) among participants in the GRACE trial, which tested darunavir (Prezista) in a study population consisting largely of women of color. Overall, they said participation was a positive experience and they would encourage others to join a clinical trial.
HIV Treatment Outcomes Improving among Transgender People
- Details
- Category: HIV Treatment
- Published on Thursday, 13 June 2013 00:00
- Written by University of Pennsylvania
Transgender people with HIV are now doing as well on antiretroviral therapy (ART) as other patients and achieving similar outcomes, according to a retrospective analysis published in the May 30, 2013, advance edition of Clinical Infectious Diseases.
Cobicistat Booster Is a Safe and Effective Alternative to Ritonavir
- Details
- Category: Experimental HIV Drugs
- Published on Thursday, 30 May 2013 00:00
- Written by Liz Highleyman
The novel pharmacoenhancer cobicistat boosts blood levels of atazanavir (Reyataz) as well as ritonavir (Norvir) and is generally safe and well-tolerated over 48 weeks, according to final study results published in the July 1, 2013, Journal of Infectious Diseases.
More Articles...
- FDA to Hold Public Meeting on Patient-Focused Drug Development and HIV Cure Research
- UNAIDS: More than 7 Million Africans on HIV Treatment, Deaths Continue to Fall
- Sangamo Reports Zinc Finger Gene Therapy Leads to Long-term CD4 Cell Gains, Shrinking HIV Reservoirs
- Very Early Antiretroviral Therapy Does Not Prevent Immune Activation
- Updated Opportunistic Infection Guidelines Add Info on IRIS, Hepatitis, Drug Interactions
Web Design and Development by